{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:05:10Z","timestamp":1789715110489,"version":"4.0.1"},"reference-count":13,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2009,7,10]],"date-time":"2009-07-10T00:00:00Z","timestamp":1247184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Bortezomib demonstrated promising activity in lymphomas. The authors conducted a randomized phase 2 trial of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R\u2010CHOP) with the addition of bortezomib in patients with B\u2010cell lymphoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients were randomized between 2 schedules of bortezomib, Arm A (Days 1, 4, 8, and 11) and Arm B (Days 1 and 8), combined with 6 cycles of R\u2010CHOP. For the first patients (Step 1), bortezomib was given at a dose of 1 mg\/m<jats:sup>2<\/jats:sup> in Arm A and 1.3 mg\/m<jats:sup>2<\/jats:sup> in Arm B. For the next patients (Step 2), doses were increased to 1.3 mg\/m<jats:sup>2<\/jats:sup> and 1.6 mg\/m<jats:sup>2<\/jats:sup> in Arms A and B, respectively. The primary endpoint was the rate of complete response (CR) and unconfirmed CR (CR\/CRu) after 6 cycles.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Forty\u2010nine patients were included in the study, and 41 patients (84%) achieved a CR\/CRu, ie, 18 of 20 patients (90%) in Arm A and 23 of 29 patients (79%) in Arm B. There were 6 partial responses and 2 patients with progressive disease. Neurologic toxicity occurred in 21 patients (43%) and was grade 2 in 11 patients (7 patients in Step 2) and grade 3 in 10 patients (9 patients in Step 2). Other grade 3 and 4 toxicities included constipation (n = 1), infections (n = 3), and cardiac events (n = 2). Grade 3 and 4 thrombocytopenia and leucopenia occurred in 14% and 41% of cycles, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>R\u2010CHOP + bortezomib was an effective regimen and produced an 84% CR rate. However, the dose\u2010limiting neurotoxicity should be kept in mind for further trials with vinca alkaloids or other potentially neurotoxic drugs combination therapies. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24518","type":"journal-article","created":{"date-parts":[[2009,7,10]],"date-time":"2009-07-10T20:13:14Z","timestamp":1247256794000},"page":"4540-4546","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B\u2010cell lymphoma"],"prefix":"10.1002","volume":"115","author":[{"given":"Vincent","family":"Ribrag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Baptiste","family":"Golfier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Ertault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Ferme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josette","family":"Briere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mounier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780100620"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl316"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2911"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1200\/jco.2007.25.18_suppl.8031","article-title":"CHOP\u2010R + bortezomib as initial therapy for diffuse large B\u2010cell lymphoma (DLBCL)","volume":"25","author":"Leonard JP","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1182\/blood.V112.11.265.265","article-title":"VcR\u2010CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin Oncology Network","volume":"112","author":"Kahl B","year":"2008","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24518","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:06:09Z","timestamp":1760285169000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24518"}},"subtitle":["A randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)"],"short-title":[],"issued":{"date-parts":[[2009,7,10]]},"references-count":13,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1002\/cncr.24518"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24518","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,10]]}}}